On the afternoon of June 5, 2023, the Deputy Director of the State Drug Administration, Huang Guo, welcomed Roberto Gaspari, Head of the World Health Organisation Regulation and Prequalification, who was visiting China. The two parties engaged in a productive meeting that covered a wide range of topics related to China's regulatory system for medical products.

Huang Guo shares progress and challenges in strengthening China’s regulatory system.

During the meeting, Huang Guo shared the latest updates on the progress China has made in strengthening its regulatory system for medical products. He provided comprehensive details on the steps taken to address the challenges faced by the regulatory authorities in China. In particular, he explained how the Science and Technology Department, Comprehensive Department, Political and Legal Department, Drug Registration Department, Drug Regulatory Department, Medical Device Registration Department, and Medical Device Regulatory Department of the State Drug Administration have been working together to identify areas for improvement in China's regulatory system. Huang Guo emphasised the importance of maintaining a robust regulatory system to ensure the safety and efficacy of medical products in the country.

Gaspari proposes joint initiatives and shares insights on regulatory systems in other countries.

Gaspari appreciated the progress made by China and suggested that the country could benefit from further collaboration with the World Health Organisation. He proposed several joint initiatives, such as research and development, technical assistance, and capacity building. In addition to that, he shared his experiences and insights on the regulatory systems in other countries. He explained how these initiatives could help strengthen the regulatory system in China and emphasised the need to learn from the best practises of other countries to achieve this goal.

Huang Guo thanks Gaspari and acknowledges the contributions of relevant departments.

Huang Guo thanked Gaspari for his valuable insights and expressed his commitment to promoting cooperation with the World Health Organisation. He acknowledged the contributions of the relevant responsible comrades from the Science and Technology Department, Comprehensive Department, Political and Legal Department, Drug Registration Department, Drug Regulatory Department, Medical Device Registration Department, and Medical Device Regulatory Department of the State Drug Administration. Their expertise and insights helped identify areas for improvement in China's regulatory system and paved the way for future collaborations.

Huang Guo shares a vision for the regulatory system in China and emphasises the importance of international cooperation.

Looking to the future, Huang Guo shared his vision for the regulatory system in China. He discussed how it can help drive innovation and improve the quality of medical products in the country. He highlighted the importance of international cooperation and the need to learn from the best practises of other countries to achieve this goal. The meeting between Huang Guo and Gaspari was productive and beneficial for the regulatory system in China, with both parties agreeing to continue exploring areas for future collaboration.